Teva Pharmaceutical Industries Reports Q3 2026 Results with Raised Full-Year Guidance
Teva Pharmaceutical Industries (TEVA) reported third-quarter revenue of $4.4 billion, a slight 2% decline in local currency driven by lower sales of generic Revlimid in the U.S. However, profitability metrics showed strength; non-GAAP diluted EPS rose 10% year-over-year to $0.86, and adjusted EBITDA increased 7% to $1.5 billion. The company achieved its highest quarterly non-GAAP gross margin in a decade at 58.7%, excluding certain development milestone payments. Growth was driven by the specialty portfolio, with AUSTEDO revenue up 21% and AJOVY revenue surging 61%. Due to this momentum, Teva raised its full-year revenue guidance to a range of $16.7 billion to $17.0 billion. Additionally, the company reached its 2027 biosimilar revenue target one year early and successfully achieved investment-grade credit ratings from Moody's, S&P, and Fitch.
Topics: EBITDA EPS gross margin guidance product performance revenue